Are there any conditions for when one peginterferon is safer or more effective than another, when given with ribavirin to treat chronic hepatitis C?
There are almost no data to determine whether the efficacy or safety of peginterferons varies according to race, gender, age, presence of obesity, severity of baseline disease (e.g., higher viral loads, more severe fibrosis or inflammation) or other comorbid conditions (e.g., co-infection with HIV).
Related Questions
- Are there any conditions for when one peginterferon is safer or more effective than another, when given with ribavirin to treat chronic hepatitis C?
- Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease?
- What is the most effective way to treat ADHD (attention deficit hyperactivity disorder)?
